OSE Immunotherapeutics Confirms Marc Le Bozec as CEO
OSE Immunotherapeutics announces the permanent appointment of Marc Le Bozec as CEO, effective immediately. Mr. Le Bozec has been serving in this role on an interim basis since October 2, 2025.
The Board of Directors of OSE Immunotherapeutics has unanimously confirmed, upon recommendation from the Nomination and Compensation Committee, the appointment of Marc Le Bozec as the permanent CEO. This decision follows a thorough review of both internal and external candidates. Mr. Le Bozec continues from his role as interim CEO, which he has held since October 2, 2025.
Details on Compensation Policy
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The compensation policy for Marc Le Bozec in his capacity as CEO will be published in the OSE Immunotherapeutics Universal Registration Document 2025 and will be subject to the vote at the Company's Annual General Meeting, which will review the accounts for the fiscal year ending December 31, 2025.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
